LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

LLY

995.84

-1.3%↓

JNJ

201.6

-0.09%↓

ABBV

222.95

-1.45%↓

UNH

323.16

-2.22%↓

AZN

91.2

+1.13%↑

Home・Akciju saraksts・Charles River Laboratories International Inc

Charles River Laboratories International Inc

Slēgts

SektorsVeselības aprūpe

187.16 1.48

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

182.95

Max

188.83

Galvenie mērījumi
By Trading Economics
Ienākumi	2.9M 56M
Pārdošana	-27M 1B
P/E Sektora vidējais	592.3 80.03
EPS	2.43
Peļņas marža	5.529
Darbinieki	18,700
EBITDA	-23M 198M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+2.88% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-136M 8.7B
Iepriekšējā atvēršanas cena	185.68
Iepriekšējā slēgšanas cena	187.16

Ziņu noskaņojums

By Acuity

56%

44%

308 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

117.16 / 144.77 Atbalsts un pretestība

Charles River Laboratories International Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 8. dec. 23:48 UTC

Galvenie tirgus virzītāji

Shares of Sezzle and Vital Farms Rise on S&P SmallCap 600 Inclusion

2025. g. 8. dec. 23:44 UTC

Tirgus saruna

Perky Australian Dollar Looks to Extend Gains -- Market Talk

2025. g. 8. dec. 23:42 UTC

Tirgus saruna

Nikkei May Decline Amid Uncertainty Over Econ, Earnings -- Market Talk

2025. g. 8. dec. 23:13 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 8. dec. 23:13 UTC

Tirgus saruna

Australian Inflation Expectations Highest Since Late 2023 -- Market Talk

2025. g. 8. dec. 23:09 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Made a Hostile Bid for Warner After Netflix Deal. What Happens Next? -- WSJ

2025. g. 8. dec. 22:46 UTC

Tirgus saruna

Rio Tinto Building Low-Cost Lithium Business in Difficult Market -- Market Talk

2025. g. 8. dec. 22:01 UTC

Tirgus saruna

Miners Poised to Do Well in 2026 -- Market Talk

2025. g. 8. dec. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Noble: Agreement With Borr Includes Sale of Noble Tom Prosser, Noble Mick O'Brien, Noble Regina Allen, Noble Resilient, Noble Resolute, Closing Expected in Early 2026 >NE

2025. g. 8. dec. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Noble: Agreement With Borr Comprises $210M in Cash and $150M in Seller Notes >NE

2025. g. 8. dec. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Noble: Agreement With Ocean Oilfield Drilling Anticipates the Sale of the Noble Resolve, Closing Is Expected in 2Q 2026, Upon Conclusion of Noble Resolve's Current Contract >NE

2025. g. 8. dec. 22:00 UTC

Iegādes, apvienošanās, pārņemšana

Noble: To Sell Five Rigs to Borr Drilling Limited for $360M and One Rig to Ocean Oilfield Drilling for $64M in Cash >NE

2025. g. 8. dec. 21:51 UTC

Tirgus saruna

US-Canada Rate Spreads Narrow Sharply After Record Gap -- Market Talk

2025. g. 8. dec. 21:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Tech, Media & Telecom Roundup: Market Talk

2025. g. 8. dec. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 8. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 8. dec. 21:38 UTC

Iegādes, apvienošanās, pārņemšana

Boeing Buys Company Responsible for Door Blowout. The Stock Rises. -- Barrons.com

2025. g. 8. dec. 21:38 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Makes $77.9 Billion Hostile Bid for Warner After Netflix Struck Deal -- 7th Update

2025. g. 8. dec. 21:36 UTC

Tirgus saruna

Oil Oversupply to Show Up As Waterborne Stocks Land -- Market Talk

2025. g. 8. dec. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Will the Netflix-Warner Bros. Merger Go Through? It Depends on How You Define Market Share. -- Barrons.com

2025. g. 8. dec. 21:12 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Moved the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

2025. g. 8. dec. 21:08 UTC

Tirgus saruna

Rosenberg Turns 'Outright Bullish' on Canada Dollar -- Market Talk

2025. g. 8. dec. 20:38 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Netflix Co-CEOs Confident About Regulatory Approval for WBD Deal -- Market Talk

2025. g. 8. dec. 20:26 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Warner Bros., Paramount, Netflix, Tesla, CoreWeave, Confluent, Marvell, Carvana, and More -- Barrons.com

2025. g. 8. dec. 20:18 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Netflix Isn't Looking to Make Cuts at Warner Bros. Discovery -- Market Talk

2025. g. 8. dec. 20:07 UTC

Tirgus saruna

Oil Futures Snap Three-Session Winning Streak -- Market Talk

2025. g. 8. dec. 20:06 UTC

Tirgus saruna

U.S. Natural Gas Pulls Back From Weather-Driven Highs -- Market Talk

2025. g. 8. dec. 20:05 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 8. dec. 20:05 UTC

Tirgus saruna

Deere Offers Sales Growth Forecast Through 2030 -- Market Talk

2025. g. 8. dec. 20:01 UTC

Tirgus saruna

Precious Metals Slip Ahead of Fed Decision -- Market Talk

Salīdzinājums

Cenas izmaiņa

Charles River Laboratories International Inc Prognoze

Cenas mērķis

By TipRanks

2.88% augšup

Prognoze 12 mēnešiem

Vidējais 192.5 USD 2.88%

Augstākais 225 USD

Zemākais 165 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 11 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Charles River Laboratories International Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

117.16 / 144.77Atbalsts un pretestība

Recent bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

308 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.